Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics, Inc. reported that SVP and Chief Financial Officer Latha Vairavan disposed of 435 shares of common stock at $21.05 per share. According to the footnote, the shares were sold to cover tax withholding obligations tied to vesting of Restricted Stock Units. Following this routine tax-related sale, Vairavan directly holds 85,978 common shares.
Arcutis Biotherapeutics, Inc. officer Patrick Burnett reported an open-market sale of 222 shares of common stock at $21.05 per share. According to the footnote, this sale was made solely to cover tax withholding obligations tied to the vesting of Restricted Stock Units. After the transaction, Burnett directly owned 120,244 shares, so the sale represents a very small portion of his holdings and reflects a compensation-related tax event rather than a discretionary reduction in his investment.
Arcutis Biotherapeutics reported a Schedule 13G filing showing State Street Corporation beneficially owns 6,296,197 shares of Common Stock. The filing states this equals 5.1% of the class and lists 03/31/2026 as the reporting date. The filing attributes shared voting power of 5,996,079 and shared dispositive power of 6,296,197 to State Street and names several State Street advisory subsidiaries in Item 7.
Arcutis Biotherapeutics submitted a Form 144 notice dated 05/11/2026 reporting proposed sales related to vested restricted common stock. The filing lists a restricted stock vesting event dated 05/01/2026 and shows recent dispositions of 684 shares on 05/04/2026 and 6,287 shares on 03/02/2026.
This notice identifies the reporting person Patrick Burnett and provides addresses and dollar amounts tied to the recent dispositions; the filing documents a proposed sale process rather than completed market impact or company financial data.
Arcutis Biotherapeutics submitted a Form 144 notice relating to proposed sales of Common Stock. The filing lists 435 shares tied to Restricted Stock Vesting with an effective date of 05/01/2026. The filing also shows prior dispositions of 2,853 shares on 03/02/2026 and 1,341 shares on 05/04/2026.
Prudential Financial, Inc. filed an Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 5,302,713 shares of Arcutis Biotherapeutics Common Stock as of 03/31/2026, representing 4.3% of the class. The filing states Prudential is a Parent Holding Company and lists subsidiaries as indirect holders, including Jennison Associates LLC 4,980,770 and PGIM Quantitative Solutions LLC 256,545. The filing also discloses voting and dispositive power breakdowns: sole voting power 25,800, shared voting power 4,928,346, sole dispositive power 25,800, and shared dispositive power 5,276,913.
Arcutis Biotherapeutics, Inc. officer Masaru Matsuda reported selling 8,256 shares of common stock on May 4, 2026 in open-market transactions. The filing states these sales were made to cover tax withholding obligations arising from the vesting of Restricted Stock Units.
The transactions were executed under a Rule 10b5-1 trading plan adopted on June 5, 2025, with a plan end date of September 4, 2026. Shares were sold at weighted average prices of $23.6106 and $23.2696 per share across multiple trades within disclosed price ranges. Following the sales, Matsuda directly holds 126,689 shares of Arcutis common stock.
Arcutis Biotherapeutics insider files Form 4 for a small tax-related sale. Officer Patrick Burnett sold 684 shares of common stock on May 4, 2026 at a weighted average price of $23.6106 per share. The footnotes state the sale was made solely to cover tax withholding obligations from vesting Restricted Stock Units. After this transaction, Burnett directly holds 120,466 shares of Arcutis common stock.
Arcutis Biotherapeutics SVP and CFO Latha Vairavan disposed of 1,341 shares of Common Stock in a tax-related sale. The shares were sold on May 4, 2026 at a weighted average price of $23.6106 per share.
According to the disclosure, the sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units, rather than as a discretionary portfolio trade. After this transaction, Vairavan directly holds 86,413 shares of Arcutis Biotherapeutics common stock.
The sale price reflects multiple trades executed in a range from $23.16 to $23.93 per share, with the weighted average reported in the filing.
Arcutis Biotherapeutics, Inc. director and officer Todd Watanabe reported an insider transaction involving company common stock. On May 4, 2026, he sold 3,172 shares at a weighted average price of $23.6106 per share. According to the filing, this sale was made to cover tax withholding obligations tied to the vesting of Restricted Stock Units, rather than a discretionary portfolio move.
Following the sale, Watanabe directly holds 720,755 common shares. The filing also lists additional indirect holdings through several trusts and an LLC, for which he is trustee or officer and where he disclaims beneficial ownership except for any pecuniary interest.